Effects of ACE-inhibition on IGF-1 and IGFBP-3 concentrations in older adults with high cardiovascular risk profile

被引：1
作者：
Giovannini S. [1 ,2 ]
Cesari M. [2 ]
Marzetti E. [1 ]
Leeuwenburgh C. [1 ]
Maggio M. [3 ]
Pahor M. [1 ]
机构：
[1] Dept. of Aging and Geriatric Research, Division of Biology of Aging, University of Florida - Institute on Aging, Gainesville, FL 32610
[2] Department of Gerontological, Geriatric and Physiatric Sciences, Catholic University of the Sacred Heart, Rome
[3] Department of Internal Medicine and Biomedical Sciences, Section of Geriatrics, University of Parma
来源：
The journal of nutrition, health & aging | 2010年 / 14卷 / 6期
基金：
美国国家卫生研究院;
关键词：
Angiotensin converting enzyme inhibitor; Insulin like growth factor 1; Insulin like growth factor binding protein 3; Older adults;
D O I：
10.1007/s12603-010-0036-7
中图分类号：
学科分类号：
摘要：
Objectives: The present study evaluates the effects of a 6-month treatment with an ACE-inhibitor (ie, fosinopril) on serum concentrations of total IGF-1 and IGF binding protein (IGFBP)-3 in older adults at high risk for cardiovascular disease. Design: Data are from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study, a double-blind, crossover, randomized, placebo-controlled trial. Setting: Participants were recruited from the communities of Winston Salem, NC, and Greensboro, NC. Participants: Subjects ≥55 years old with high cardiovascular disease risk profile. Intervention: The intervention consisted of 6-month administration of fosinopril vs. placebo. Measurements: Serum concentrations of total IGF-1 and IGFBP-3 were measured in 100 participants of the TRAIN study at baseline, 6-month and 12-month follow-up visits. Differences in total IGF-1 and IGFBP-3 concentrations were assessed using two-sided paired t-tests. Results: The mean age of participants (47% women) was 66.5 (standard deviation 7.2) years. Serum concentrations of total IGF-1 were significantly higher after 6-month treatment with fosinopril compared to placebo (203.73 ng/mL vs 194.24 ng/mL; p=0.02): After ACE-inhibitor intervention, significantly higher serum IGFBP-3 concentrations compared to controls (4308.81 ng/mL vs 4086.93 ng/mL; p=0.03) were also reported. Conclusions: A six-month treatment with fosinopril increases systemic levels of total IGF-1 and IGFBP-3 in older adults with high cardiovascular risk profile. This may represent a potential biological explanation to the beneficial effects of ACE-inhibition on stroke, ischemic heart disease and insulin resistance. The Journal of Nutrition, Health & Aging©.
引用
收藏
页码：457 / 460
页数：3
相关论文
共 20 条
[1]  
Fox K.M., Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study), Lancet, 362, 9386, pp. 782-788, (2003)
[2]  
Yusuf S., Gerstein H., Hoogwerf B., Et al., Ramipril and the development of diabetes, JAMA, 286, 15, pp. 1882-1885, (2001)
[3]  
Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, N Engl J Med, 342, 3, pp. 145-153, (2000)
[4]  
Maggio M., Ceda G.P., Lauretani F., Et al., Relation of angiotensin-converting enzyme inhibitor treatment to insulin-like growth factor-1 serum levels in subjects >65 years of age (the InCHIANTI study), Am J Cardiol, 97, 10, pp. 1525-1529, (2006)
[5]  
Onder G., Liperoti R., Russo A., Capoluongo E., Minucci A., Lulli P., Cesari M., Maggio M., Bernabei R., Landi F., Use of ACE inhibitors is associated with elevated levels of IGFBP-3 among hypertensive older adults: Results from the IlSIRENTE study, European Journal of Clinical Pharmacology, 63, 4, pp. 389-395, (2007)
[6]  
Brink M., Wellen J., Delafontaine P., Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism, Journal of Clinical Investigation, 97, 11, pp. 2509-2516, (1996)
[7]  
Colao A., Spiezia S., Di S.C., Et al., Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age, J Endocrinol Invest, 28, 5, pp. 440-448, (2005)
[8]  
Martin R.M., Gunnell D., Whitley E., Et al., Associations of insulin-like growth factor (IGF)-I, IGF-II, IGF binding protein (IGFBP)-2 and IGFBP-3 with ultrasound measures of atherosclerosis and plaque stability in an older adult population, J Clin Endocrinol Metab, 93, 4, pp. 1331-1338, (2008)
[9]  
Valentinis B., Bhala A., DeAngelis T., Baserga R., Cohen P., The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene, Mol Endocrinol, 9, 3, pp. 361-367, (1995)
[10]  
Rajah R., Valentinis B., Cohen P., Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- And IGF-independent mechanism, J Biol Chem, 272, 18, pp. 12181-12188, (1997)
12